First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
A primary investment of Rs 194.4 crore has been made
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
The curriculum has been curated for General Physicians working in Clinikk
Multiples is the first private equity (PE) investor in the company
They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
Subscribe To Our Newsletter & Stay Updated
